Literature DB >> 28249131

Conflicts of Interest for Patient-Advocacy Organizations.

Matthew S McCoy1, Michael Carniol1, Katherine Chockley1, John W Urwin1, Ezekiel J Emanuel1, Harald Schmidt1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28249131     DOI: 10.1056/NEJMsr1610625

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  31 in total

1.  Author's Reply to Braillon: "Moving from Patient Advocacy to Partnership: A Long and Bumpy Road".

Authors:  Durhane Wong-Rieger
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

2.  Real-World Evidence: Promise and Peril For Medical Product Evaluation.

Authors:  Sanket S Dhruva; Joseph S Ross; Nihar R Desai
Journal:  P T       Date:  2018-08

3.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

4.  A proposed framework for patient engagement throughout the broader research enterprise.

Authors:  Camila L Strassle; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2020-04-07       Impact factor: 1.744

5.  Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.

Authors:  David G Li; Sean Singer; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

6.  Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.

Authors:  So-Yeon Kang; Ge Bai; Laura Karas; Gerard F Anderson
Journal:  Am J Public Health       Date:  2019-02-21       Impact factor: 9.308

7.  Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.

Authors:  Sanket S Dhruva; Jonathan J Darrow; Aaron S Kesselheim; Rita F Redberg
Journal:  J Gen Intern Med       Date:  2022-02-09       Impact factor: 5.128

8.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

9.  Conflicts of interest in dialysis: A barrier to policy reforms.

Authors:  Aaron Glickman; Eugene Lin; Jeffrey S Berns
Journal:  Semin Dial       Date:  2020-01-03       Impact factor: 3.455

Review 10.  FDA Drug Approval and the Ethics of Desperation.

Authors:  Emily A Largent; Andrew Peterson; Holly Fernandez Lynch
Journal:  JAMA Intern Med       Date:  2021-12-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.